The company unveils that TNFR2 is the target for BI-1808, a receptor that predominantly is expressed on Tregs in the tumor microenvironment. According to Bioinvent, preclinical data are to be submitted for publication later this year. At this point, without any further data, it is not possible to have an opinion on the potential of BI-1808. It is an exciting target, and BI-1808 might be an attractive asset for partnering given its uniqueness.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se